



Luc Perrin

Kontakt

Luc Perrin

Publikationen (14)

von Wyl V, Günthard H, Ledergerber B, Perrin L, Rickenbach M, Bernasconi E, Vernazza P, Hirschel B, Telenti A, Furrer H, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. *Archives of internal medicine* 2007; 167:1782-90.

Ananworanich J, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B, Staccato Study Group, Bernasconi E, Vernazza P, Nüesch R, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genné D, Swiss HIV Cohort Study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. *Lancet* 2006; 368:459-65.

Müller V, Bonhoeffer S, Günthard H, Vernazza P, Bernasconi E, Telenti A, Furrer H, Klimkait T, Perrin L, Ledergerber B, Swiss HIV Cohort Study. Stable virulence levels in the HIV epidemic of Switzerland over two decades. *AIDS (London, England)* 2006; 20:889-94.

Schüpbach J, Hirschel B, Bernasconi E, Vernazza P, Furrer H, Battegay M, Perrin L, Yerly S, Tomasik Z, Böni J, Fischer M, Joos B, Günthard H, Swiss HIV Cohort Study. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. *Journal of acquired immune deficiency syndromes (1999)* 2005; 40:250-6.

Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Perrin L, Ledergerber B, Furrer H, Swiss HIV Cohort Study. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2005; 41:361-72.

Opravil M, Perrin L, Ledergerber B, Vernazza P, Blasko M, Bernasconi E, Calmy A, Furrer H, Chave J, Baumann D, Swiss HIV Cohort Study. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. *AIDS (London, England)* 2004; 18:2213-5.

Yerly S, Perrin L, Hirschel B, Perneger T, Bernard M, Gebhardt M, Rickenbach M, Bürgisser P, Chanzy B, Furrer H, Battegay M, Vernazza P, Chave J, Kaiser L, Flepp M, Telenti A, Jost S, Swiss HIV Cohort Study. Infrequent transmission of HIV-1 drug-resistant variants. *Antiviral therapy* 2004; 9:375-84.

Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Vernazza P, Ledergerber B, Cavassini M, Furrer H, Perrin L, Weber R, Khanna N, Swiss HIV Cohort Study. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. *Antiviral therapy* 2004; 9:263-74.

Kaufmann G, Battegay M, Egger M, Rickenbach M, Bernasconi E, Vernazza P, Ledergerber B, Hirschel B, Telenti A, Furrer H, Opravil M, Pantaleo G, Perrin L, Swiss HIV Cohort Study Group. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. *Archives of internal medicine* 2003; 163:2187-95.

Hadaya K, Wunderli W, Deffernez C, Martin P, Mentha G, Binet F, Perrin L, Kaiser L. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. *Journal of clinical microbiology* 2003; 41:3757-64.

Fagard C, Hirschel B, Perrin L, Perneger T, Oxenius A, Ebnöther C, Telenti A, Bernasconi E, Vernazza P, Egger M, Hirsch H, Günthard H, Le Braz M, Swiss HIV Cohort Study. A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. *AIDS (London, England)* 2003; 17:1487-92.

Fagard C, Price D, Dawson S, Klimkait T, Perneger T, McLean A, Clotet B, Gatell J, Perrin L, Plana M, Phillips R, Hirschel B, Yerly S, Leduc D, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Swiss HIV Cohort Study. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. *Archives of internal medicine* 2003; 163:1220-6.

Greub G, Telenti A, Phillips A, Hirschel B, Günthard H, Bernasconi E, Vernazza P, Battegay M, Furrer H, Francioli P, Miller V, Perrin L, Staszewski S, Ledergerber B, Cozzi-Lepri A, Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. *AIDS (London, England)* 2002; 16:1967-9.

Opravil M, Perrin L, Weber R, Howe C, Günthard H, Ledergerber B, Battegay M, Bernasconi E, Vernazza P, Fischer M, Bisset L, Yerly S, Chave J, Furrer H, Lazzarin A, Hirschel B, Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. *The Journal of infectious diseases* 2002; 185:1251-60.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch